Chief Executive Officer
As a cofounder of the company, Dr. Cato created and maintains the corporate vision. In addition, he directs sponsor interactions, and seeks business opportunities and strategic alliances with other companies and organizations. Dr. Cato serves as an advisor on project teams and develops complex strategic development plans and study designs. He maintains hands-on experience with all phases of the development process, and is especially skillful in devising regulatory and clinical strategies and representing sponsors at regulatory meetings. Dr. Cato has more than 35 years of experience in clinical research and new drug development. He has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato's areas of expertise include the following: clinical pharmacokinetics, biostatistics, drug surveillance, pharmacoepidemiology, adverse drug reactions, clinical study design, regulatory interactions, pulmonary and pediatric medicine, and clinical research and development. Dr. Cato has published hundreds of papers, principally in the fields of clinical pharmaceutical research, cystic fibrosis, gene therapy and global drug development. He serves as a member of the board of directors for several pharmaceutical and biotechnology companies.